New Recombinant Factor IX Treatment Approved by the FDA

Horizons in Hemophilia, September 2013

By Leigh Carpenter, RPh, Director of Pharmacy

Baxter has announced that the Food and Drug Administration (FDA) has approved RIXUBIS for hemophilia B.  It is the first new recombinant factor IX product approved in more than 15 years.  The approved indication is for both routine prophylaxis and control of bleeding episodes for those 16 years of age and older.  We expect the new factor product to be available in our pharmacies the first of October.  The sizes will be in the 250, 500, 1000 and 3000 unit ranges.  A 2000 unit range will be available in November.  We will provide more information as it becomes available in future editions of our newsletter and on our websites.  Please contact your physician or Hemophilia Treatment Center if you have interest in obtaining a prescription for RIXUBIS.